Cancer Letters
Volume 234, Issue 2 , Pages 176-183 , 28 March 2006

Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters

  • Yan J. Song

      Affiliations

    • Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    • University of New South Wales, NSW 2052, Australia
    • ,
  • Chang F. Qu

      Affiliations

    • Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    • University of New South Wales, NSW 2052, Australia
    • ,
  • Syed M.A. Rizvi

      Affiliations

    • Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    • ,
  • Yong Li

      Affiliations

    • Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    • ,
  • G. Robertson

      Affiliations

    • University of New South Wales, NSW 2052, Australia
    • Department of Genecology, St George Hospital, NSW Australia
    • ,
  • Chand Raja

      Affiliations

    • Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    • ,
  • Alfred Morgenstern

      Affiliations

    • European Commission, Joint Research Centre, Institute for Transuranium Elements, 76125 Karlsruhe, Germany
    • ,
  • Christos Apostolidis

      Affiliations

    • European Commission, Joint Research Centre, Institute for Transuranium Elements, 76125 Karlsruhe, Germany
    • ,
  • Alan C. Perkins

      Affiliations

    • Department of Medical Physics, Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK
    • ,
  • Barry J. Allen

      Affiliations

    • Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    • University of New South Wales, NSW 2052, Australia
    • Corresponding Author InformationCorresponding author. Address: Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia. Tel.: +61 2 9350 3855; fax: +61 2 9350 2316.

Received 16 December 2004 ,Revised 12 March 2005 ,Accepted 22 March 2005.

References 

  1. Bolis G, Villa A, Guarnerio P, Ferraris C, Gavoni N, Giardina G, et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer. 1996;77(1):128–131
  2. Allen BJ. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australasian Radiology. 1999;43(4):480–486
  3. Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science. 1982;215(4539):1511–1513
  4. Allen BJ. Can alpha-immunotherapy succeed where other systemic modalities have failed?. Nuclear Medicine Communications. 1999;20(3):205–207
  5. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al. An alpha-particle emitting antibody. Cancer Research. 2000;60(21):6095–6100
  6. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular & Molecular Life Sciences. 2000;57(1):25–40
  7. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 1995;86(11):4007–4024
  8. Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, Symonds IM, et al. C595-a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. British Journal of Cancer. 1990;61(5):681–686
  9. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. Journal of Biological Chemistry. 1988;263(26):12820–12823
  10. Wang JY, Chang CT, Hsieh JS, Lee LW, Huang TJ, Chai CY, et al. Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas. Journal of Surgical Oncology. 2003;83(4):253–260
  11. Croce MV, Isla-Larrain MT, Rua CE, Rabassa ME, Gendler SJ, Segal-Eiras A. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer. Journal of Histochemistry & Cytochemistry. 2003;51(6):781–788
  12. Teruya-Feldstein J, Donnelly GB, Goy A, Hegde A, Nanjangud G, Qin J, et al. MUC-1 mucin protein expression in B-cell lymphomas. Applied Immunohistochemistry & Molecular Morphology. 2003;11(1):28–32
  13. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUCl and MUC2 mucin gene products human ovarian carcinomas. Japanese Journal of Clinical Oncology. 2002;32(12):525–529
  14. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUCl mucin in breast cancer cells. European Journal of Biochemistry. 1995;233(2):607–617
  15. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Research. 2001;61(6):2420–2423
  16. Carter P, Presta L, Gorman CM, Ridgway J, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(10):4285–4289
  17. Borgfeldt C, Bendahl PO, Gustavsson B, Langstrom E, Ferno M, Willen R, et al. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Intemational Journal of Cancer. 2003;107(4):658–665
  18. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clinical Cancer Research. 2001;7(6):1743–1749
  19. Giuntoli RL, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA. Mucin gene expression in ovarian cancers. Cancer Research. 1998;58(23):5546–5550
  20. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I–II) epithelial ovarian carcinoma. International Journal of Gynecological Cancer. 2001;11(2):119–129
  21. Marian TS, Rainaldi G. Three-dimensional spheroid model in tumor biology. Pathbiology. 1999;67:148–157
  22. Griffiths SJ, Heelis PF, Haylett AK, Moore JV. Photodynamic therapy of ovarian tumours and normal cells using 5,10,15,20-tetra-(3-carboxymethoxyphenyl)-chlorin. Cancer Letters. 1998;125(l-2):177–184
  23. Abbas Rizvi SM, Sarkar S, Goozee G, Allen BJ. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Research. 2000;10(3):281–289
  24. Li Y, Rizvi SM, Ranson M, Allen BJ. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. British Journal of Cancer. 2002;86(7):1197–1203
  25. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiation Research. 1992;130(2):220–226

PII: S0304-3835(05)00330-7

doi: 10.1016/j.canlet.2005.03.060

Cancer Letters
Volume 234, Issue 2 , Pages 176-183 , 28 March 2006

Article Tools

* Image Usage & Resolution